VEGF Assays Under Scrutiny: Are We Measuring What We Think We Are?
"Experts question the reliability of VEGF measurements in the presence of anti-VEGF therapies, urging careful interpretation of assay results."
Vascular Endothelial Growth Factor (VEGF) plays a vital role in angiogenesis, the process through which new blood vessels form. Because of its importance in various diseases, including several ocular diseases, accurately measuring VEGF levels is crucial for research and treatment. Many clinical studies use anti-VEGF (anti-Vascular Endothelial Growth Factor) therapies to manage conditions like neovascular age-related macular degeneration (AMD) and diabetic macular edema (DME).
These therapies work by inhibiting VEGF, aiming to reduce abnormal blood vessel growth. Yet, measuring VEGF levels in the presence of anti-VEGF drugs presents challenges. Researchers have raised concerns about the accuracy of common VEGF assays when anti-VEGF therapeutics are also present in the samples, suggesting that these drugs can interfere with the assay results, leading to potential misinterpretations.
This article addresses the issues surrounding VEGF measurements when anti-VEGF therapies are used, delving into the complexities and offering insights to help clarify what these assays actually measure. Understanding these nuances is essential for clinicians and researchers alike, ensuring informed decisions about treatment and further study.
Why Measurement Matters
VEGF assay results can be difficult to interpret when biological samples contain anti-VEGF treatments or other interfering factors. The measured concentration may not correspond straightforwardly to the amount of biologically available VEGF. As a result, assay findings should be treated cautiously, particularly when they are used to assess treatment effects or systemic safety.
Assays and Interference
The Quantikine Human VEGF Immunoassay from R&D Systems has been evaluated in the presence of VEGF inhibitors including aflibercept, ranibizumab, and bevacizumab. In that evaluation, the anti-VEGF165 monoclonal antibody had threefold weaker binding affinity for VEGF than aflibercept, but 33- and 40-fold stronger affinity than other compared interactions reported in the study. Promega's VEGF Bioassay instead uses a bioluminescent cell-based readout of VEGF stimulation and inhibition of KDR, also known as VEGFR2, through an NFAT response element, and is presented as addressing limitations of endothelial-cell proliferation assays.
From Discovery to Therapy
Intravitreal anti-vascular endothelial growth factor therapy has a relatively young history, despite becoming a common part of contemporary medical retina practice. The American Society of Retina Specialists' historical account describes anti-VEGF development through first-hand perspectives from Joan Miller, Julia Haller, Jeffrey Heier, and Jay Duker. Another ASRS milestone account frames the VEGF story as a progression from the discovery of Factor X to the widespread use of anti-VEGF therapy for retinal conditions, while current scrutiny focuses on whether assays remain reliable alongside these treatments.
The Central Question: What Do VEGF Assays Really Measure?
The primary concern revolves around what VEGF assays are truly measuring when anti-VEGF therapies are involved. Some assays may only detect the 'free' or unbound VEGF, meaning the VEGF that is not already bound to an anti-VEGF drug. This is important because anti-VEGF molecules, designed to bind and neutralize VEGF, can impact the assay's ability to accurately quantify the total VEGF present.
- Free vs. Bound VEGF: Assays may predominantly measure unbound VEGF, potentially underestimating the total VEGF in samples with anti-VEGF drugs.
- Interference from Anti-VEGF Drugs: The presence of these drugs can physically block VEGF detection or alter assay dynamics.
- Clinical Implications: Misinterpreting VEGF levels could lead to incorrect assessments of treatment efficacy and safety.
An Evolving Evidence Base
Recent work continues to examine how VEGF assays should be interpreted in clinical and therapeutic settings. The field appears to be moving toward greater attention to assay context, including treatment exposure and the distinction between measured VEGF and biologically available VEGF. These developments suggest that assay results may be most useful when considered alongside method-specific limitations rather than treated as universally interchangeable measurements.
Where Results Can Mislead
A central concern is that an assay may report a technically valid signal without capturing the biological quantity a researcher intends to measure. Anti-VEGF drugs can alter the relationship between total VEGF, unbound VEGF, and assay-detected VEGF. This creates a risk that apparently precise results could support misleading conclusions if drug interference and assay design are not considered.
Total Versus Free VEGF
Total VEGF assays require high drug tolerance and processing steps to dissociate VEGF from anti-VEGF drugs, but Celerion reports that these steps can negatively affect accuracy and precision. Free VEGF assays are commonly performed with commercial ELISA kits, although recent studies cited by Celerion indicate that some kits do not accurately measure either total or free VEGF. A separate discussion emphasizes that assays using reagents directed at anti-VEGF binding sites cannot measure VEGF while it is drug-bound; the resulting unbound or free VEGF is described as the biologically active species and therefore especially relevant to systemic safety assessment.
Moving Forward: Best Practices for VEGF Measurement
Given these concerns, experts recommend a cautious approach to interpreting VEGF assay results in the context of anti-VEGF therapies. Researchers and clinicians should be aware of the limitations of each assay and consider the potential for interference. Ensuring the accuracy of VEGF measurements will not only enhance the reliability of research findings but also improve patient care.
Preanalytical Context Matters
A systematic review and meta-analysis examined concerns about systemic VEGF levels in preterm infants receiving anti-VEGF treatment. Earlier studies had suggested that preanalytical and methodological parameters affect analytical VEGF concentrations, yet the authors noted that a comprehensive review of preanalytical procedures and VEGF methods had been lacking. The broader implication is that sample handling and analytical method should be treated as part of the result, not as separate technical details.
Toward More Predictive Tools
A 2024 review identifies new anti-VEGF drugs and drug-delivery systems as future directions after notable success in wet age-related macular degeneration and diabetic macular edema. Research is also evaluating artificial-intelligence models for predicting anti-VEGF treatment response in patients with diabetic macular edema, with emphasis on diagnostic accuracy, evidence quality, and recommendations for future studies. Aptamer-based nanobiosensors represent another emerging direction, with proposed real-time VEGF detection and quantification for clinical diagnosis and treatment. At the same time, treatment burden, variable response, and cost remain reported limitations for real-world outcomes in retinal vascular disease.
Beyond the Number
VEGF measurement sits at the intersection of laboratory technique, drug exposure, biological variability, and clinical interpretation. Differences in sample handling or assay design can make results difficult to compare across studies and settings. These challenges support a cautious approach in which VEGF values are interpreted with attention to their measurement context rather than as standalone indicators.
What Measurement Means for Care
For patients, the practical value of a VEGF assay depends on whether its result helps clinicians understand disease activity, treatment response, or safety. Uncertain or non-comparable measurements can complicate decisions even when the underlying treatment is effective. Clear reporting of assay methods and limitations can therefore help connect laboratory findings with real-world care.